The following routine monitoring is recommended after a diagnosis of SCA36 has been confirmed.

At least annual evaluation by a neurologist or more frequently if symptoms are progressing

Annual or bi-annual evaluation by an otolaryngologist to detect or monitor hearing loss

Surveillance of speech and ambulation

In presymptomatic individuals who tested positive for the NOP56 expansion, it is appropriate to start surveillance of neurologic status and hearing by age 40-45 years.
